InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.650 0.01 (1.56%)+
Announcement
Release
3 Feb 2026 8:46AM
Price at Release
$0.640
Full Release
download
Summary
Aroa Biosurgery Limited provided a business update presentation on 3 February 2026, focusing on their ongoing projects and market strategies. The presentation covered the Myriad Trauma Study, highlighting its progress with 450 patients enrolled. The Symphony product is positioned for market disruption due to reimbursement changes, and financial guidance includes a revenue target of NZ$92-100 million and an EBITDA of NZ$5-8 million. The update emphasized their commitment to advancing regenerative healing technologies.
Key Points
  • Aroa Biosurgery Limited presented a business update on 3 February 2026.
  • The presentation is intended for investor education and not as an offer of securities.
  • The Myriad Trauma Study, a large multicenter observational study, is ongoing with 450 patients enrolled.
  • The Symphony product has undergone reimbursement changes expected to disrupt the market.
  • The presentation includes forward-looking statements and financial guidance.
  • Guidance for the financial year includes a revenue target of NZ$92-100 million and EBITDA of NZ$5-8 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.